Variable | Sample set I (n = 63) | Sample set II (n = 371) | ||||
---|---|---|---|---|---|---|
 | HRa | (95% CIb) | p-value | HRa | (95% CIb) | p-value |
Haptoglobin phenotype | Â | Â | Â | Â | Â | Â |
   Hp 1-1 | 1 | - | - | 1 | - | - |
   Hp 2-1 | 4.21 | (0.44 – 39.83) | 0.2105 | 0.94 | (0.58 – 1.52) | 0.8059 |
   Hp 2-2 | 17.76 | (2.00 – 157.44) | 0.0098 | 1.26 | (0.76 – 2.08) | 0.3653 |
Surgery | Â | Â | Â | Â | Â | Â |
   Breast conserving | 1 | - | - | 1 | - | - |
   Mastectomy | 1.26 | (0.24 – 6.67) | 0.7843 | 0.91 | (0.59 – 1.39) | 0.6514 |
Treatment arm | Â | Â | Â | Â | Â | Â |
   High dose | 1 | - | - | 1 | - | - |
   Conventional dose | 0.33 | (0.11 – 1.00) | 0.0509 | 1.36 | (0.96 – 1.92) | 0.0809 |
Age | Â | Â | Â | Â | Â | Â |
   ≥ 40 yrs | 1 | - | - | 1 | - | - |
   < 40 yrs | 1.26 | (0.32 – 4.93) | 0.7413 | 0.97 | (0.65 – 1.46) | 0.8890 |
No. of positive lymph nodes | Â | Â | Â | Â | Â | Â |
   4 – 9 | 1 | - | - | 1 | - | - |
   ≥ 10 | 0.72 | (0.23 – 2.29) | 0.5785 | 1.00 | (0.69 – 1.45) | 0.9964 |
Tumour size | Â | Â | Â | Â | Â | Â |
   < 5 cm | 1 | - | - | 1 | - | - |
   ≥ 5 cm | 1.35 | (0.50 – 3.65) | 0.5497 | 1.63 | (1.03 – 2.60) | 0.0374 |
Her2/Neu status | Â | Â | Â | Â | Â | Â |
   Negative | 1 | - | - | 1 | - | - |
   Positive | 1.47 | (0.53 – 4.08) | 0.4641 | 1.47 | (0.99 – 2.20) | 0.0589 |
Receptor status | Â | Â | Â | Â | Â | Â |
   ER/PR positive | 1 | - | - | 1 | - | - |
   ER/PR negative | 3.39 | (0.80 – 14.27) | 0.0962 | 1.11 | (0.73 – 1.70) | 0.6138 |
Bloom-Richardson grade | Â | Â | Â | Â | Â | Â |
   Grade I | 1 | - | - | 1 | - | - |
   Grade II | 0.92 | (0.26 – 3.23) | 0.9016 | 0.87 | (0.50 – 1.50) | 0.6187 |
   Grade III | 1.28 | (0.37 – 4.46) | 0.6946 | 1.34 | (0.79 – 2.26) | 0.2796 |